AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 261 min read$EW

Chopra Daveen sold $2.9M of EW

Chopra Daveen (CVP, TMTT, Surgical & IHFM) sold 31,800 shares of Edwards Lifesciences Corp (EW) at an average of $91.02 ($90.99–$91.76, $2.89M total) across 2 trades on 2026-08-26.

Original reporting
SEC EDGAR · Chopra Daveen
Published Aug 26, 2026, 10:36 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$EW
Bearish
medium confidence
Mentioned
$EW
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EWBearishLow
01

Why it matters

The disclosed sale reduces the insider's ownership but does not indicate a material change in control.

02

Market read

A routine insider sale with modest size; likely limited market impact.

03

What to watch

Potential upcoming earnings release or corporate actions that may have prompted the sale.

Relevance 6/10Novelty 5/10Timing: filing date 2026-08-26

Background

Edwards Lifesciences (EW) is a leading medical device company. Insider transactions are disclosed via Form 4 filings.

Company-level read

Ticker impact

$EWBearishMedium confidence
Context

Officer Chopra Daveen sold 31,800 shares of Edwards Lifesciences for $2.9M, reducing his stake to 44,324 shares.

Expected impact

Possible modest downside pressure in the next trading session.

Evidence & confidence

Sale size is notable for a senior officer but not large enough to cause a major move; market may react modestly.

Market effects

Sector

Minimal impact on the medical device sector; insider sales are common and rarely shift sector sentiment.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Officer
    Chopra Daveen

    CVP, TMTT, Surgical & IHFM at Edwards Lifesciences

  • Company
    Edwards Lifesciences Corp

    Medical device manufacturer listed on NYSE under ticker EW

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EW insider trading history →

Related articles

AUG 27
$EWHighAI 8/10

Edwards Lifesciences CVP Daveen Chopra sells $2.9m in stock

Edwards Lifesciences CVP Daveen Chopra sold 31,800 shares for $2.89m after exercising options. Shares were sold at $90.99-$91.76 each. Chopra now holds 44,324 shares. Edwards Lifesciences reported Q2 earnings of $0.78 EPS and $1.74B revenue, raising full-year outlook. Analysts updated price targets and ratings.

investing.com2 min
AUG 20
$EWMed

Should You Hold Edwards Lifesciences Stock in Your Portfolio?

Edwards Lifesciences (EW) reports growth in its TMTT and TAVR businesses, with Q2 2026 sales up 10.5% and 44.8% respectively. The company faces risks from currency fluctuations and competition. EW's stock gained 16.9% over the past year, outperforming its industry. Earnings yield is 3.3%, and the company expects 2026 gross margin near the lower end of its range.

zacks.com2 min
AUG 5
$EWMedAI 8/10

FTC Reaches $12 Million Settlement Over Alleged HSR Act Violations

The FTC proposed a settlement with Edwards Lifesciences and Genesis MedTech over alleged Hart-Scott-Rodino filing violations tied to Edwards’ July 2024 $115 million acquisition of JC Medical. The FTC says a $25 million Genesis non-voting share investment was additional deal consideration, making the combined value reportable. Edwards would pay $10 million and Genesis $2 million.

mondaq.com6 min
AUG 3
$EWMedAI 8/10

Edwards Reports Q2 Sales Climb 14% to $1.74B

Edwards Lifesciences (NYSE: EW) reported Q2 revenue of $1.74B, up 14% year over year, and adjusted EPS of 78 cents, above expectations. Full-year sales guidance was raised to 10%-11%. TAVR sales grew 11% to $1.26B. CMS draft Medicare coverage could expand TAVR access, with a final decision expected in September.

ocbj.com5 min
JUL 27
$EWMedAI 8/10

Edwards Lifesciences Wins FDA Clearance for Ecliptis Left Atrial Appendage Clip

Edwards Lifesciences said the FDA cleared its Ecliptis left atrial appendage exclusion system for use during cardiac surgery to help prevent clot formation in atrial fibrillation. The company plans a preliminary launch later this year and expects to leverage its surgical valve footprint. The article also notes FDA Breakthrough designation for Aidoc’s AI and OTC Dexcom Stelo clearance for children.

thehealthcaretechnologyreport.com3 min